Bailard Inc. Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bailard Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 12,103 shares of the biopharmaceutical company’s stock after selling 31 shares during the period. Bailard Inc.’s holdings in Regeneron Pharmaceuticals were worth $10,630,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in REGN. Ronald Blue Trust Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 12 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 39 shares in the last quarter. Ritholtz Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 18.3% in the third quarter. Ritholtz Wealth Management now owns 510 shares of the biopharmaceutical company’s stock worth $420,000 after acquiring an additional 79 shares during the period. Global Retirement Partners LLC grew its position in shares of Regeneron Pharmaceuticals by 67.1% during the third quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 100 shares in the last quarter. Finally, Park Place Capital Corp raised its stake in Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 15 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Marion Mccourt sold 358 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares in the company, valued at $12,994,492.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,022 shares of company stock worth $10,552,991. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

Regeneron Pharmaceuticals stock traded down $0.78 during midday trading on Wednesday, reaching $906.54. The stock had a trading volume of 369,734 shares, compared to its average volume of 489,809. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a fifty day moving average of $950.58 and a 200 day moving average of $893.29. The firm has a market cap of $99.50 billion, a price-to-earnings ratio of 26.09, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the company earned $10.96 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.